Billionaire Stanley Druckenmiller's largest holding is Natera, a healthcare stock developing genetic diagnostic tests. Its key product, Signatera, detects cancer DNA after treatment and is ordered by roughly 50% of U.S. oncologists. First-quarter revenue rose 38% year over year, and the FDA recently approved Signatera for bladder cancer.
Tap to vote and see what everyone thinks.